Browse Category

Analyst Predictions News 8 October 2025 - 12 October 2025

Klarna (KLAR) Stock Dips Below IPO Price – Will Analysts’ Bullish Forecast Come True?

Klarna (KLAR) Stock Dips Below IPO Price – Will Analysts’ Bullish Forecast Come True?

Ticker: KLAR (NYSE) – Price (Oct 10, 2025): $38.93 marketbeat.com. Market Cap: ~$27.9B marketbeat.com. IPO Price: $40 (opened at $52) reuters.com; 52-week high ~$57.20 investopedia.com. Active Users: 111 M; Merchants: 790 K s205.q4cdn.com. Recent Moves: Down ~6% in 5 days marketbeat.com, ~9% month-to-date marketbeat.com. Analyst Consensus: Strong Buy (avg. target ~$53.5) tipranks.com, with major banks’ price targets in the $48–$58 range investopedia.com tipranks.com. Key Financials (Q2 2025): Revenue $823M, +20% YoY s205.q4cdn.com; 5th consecutive profitable quarter (Adj. Op Income $29M) s205.q4cdn.com; BNPL loan delinquencies improving (0.89% in Q2) s205.q4cdn.com. Current Price & Market Data: marketbeat.comAs of the last close on Oct. 10,
12 October 2025
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Current News & October 2025 Updates EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan (PIP) for Acurx’s lead drug, ibezapolstat, in Clostridioides difficile infection investing.com. This essentially means European regulators agree with Acurx’s plan to study ibezapolstat in children, a prerequisite for future marketing approval in Europe. As the company noted, the PIP approval “ensur[es] necessary data are obtained to support the drug’s authorization and use in pediatric populations.” investing.com This news helped lift ACXP stock from about $4.18 to $4.60 at the end of that week nasdaq.com, reflecting investor
Go toTop